Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

Kasper, Siegfried; Dötsch, M.; Kick, Hermes Andreas; Vieira, Ana Beatriz Duarte; Möller, Hans‐Jürgen

doi:10.1016/0924-977x(93)90290-3

Cited by 73 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kasper et al [26] also reported that there was no correlation between plasma concentration of fluvoxamine and antidepressant response. In this study, however, fluvoxamine levels are found to be higher in responders (mean B SD = 178 B 164.6) than non-responders (mean B SD = 110.7 B 73.3).…”

Section: Discussionmentioning

confidence: 96%

Association between -1438G/A Promoter Polymorphism in the 5-HT2A Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder

Sato

Yoshida²,

Takahashi³

et al. 2002

Neuropsychobiology

View full text Add to dashboard Cite

Genetic polymorphism of the serotonin 5-HT_2A receptor seems to be associated with therapeutic response to selective serotonin reuptake inhibitors (SSRIs). The present study investigated whether a novel –1438G/A polymorphism in the promoter region of the 5-HT_2Areceptor gene is associated with therapeutic response to fluvoxamine (an SSRI) in 66 Japanese patients with major depressive disorder. Fluvoxamine (50 to 200 mg) was administered twice daily for 6 weeks. Fifty-four patients completed this study. The genotype distribution and the allele frequencies showed no significant difference between responders and non-responders. The time-course of the Montgomery-Åsberg Depression Rating Scale scores showed no significant difference among –1438G/G, –1438G/A, and –1438A/A genotype groups. The results demonstrated that the –1438G/A promoter polymorphism in the 5-HT_2A receptor gene was unlikely to have a major role in therapeutic response to fluvoxamine in Japanese patients with major depressive disorder.

show abstract

Section: Discussionmentioning

confidence: 96%

Association between -1438G/A Promoter Polymorphism in the 5-HT2A Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder

Sato

Yoshida²,

Takahashi³

et al. 2002

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…The daily fluvoxamine dosage was higher in nonresponders and nonremitters than in responders and remitters, respectively, though this should be self-evident for a study design incorporating fixed-flexible dosing. However, these effects should be minimal since no correlation between plasma fluvoxamine concentration and clinical response has been reported [49] .…”

Section: Discussionmentioning

confidence: 99%

Genetic Association Analysis of Functional Polymorphisms in Neuronal Nitric Oxide Synthase 1 Gene (NOS1) and Mood Disorders and Fluvoxamine Response in Major Depressive Disorder in the Japanese Population

et al. 2009

View full text Add to dashboard Cite

Background/Aim: Nitric oxide has been reported to play a role in neural transmitter release and N-methyl-D-aspartate receptor activation, as well as to be related to oxidative stress. Abnormalities in both of these mechanisms are thought to be involved in the pathophysiology of mood disorders including major depressive disorder (MDD) and bipolar disorder (BP). In addition, several lines of evidence support an association between abnormalities in neuronal nitric oxide synthases (nNOS) and mood disorders. Therefore, we studied the association of nNOS gene (NOS1) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients. Materials and Methods: Using a single nucleotide polymorphism (SNP; rs41279104, also called ex1c), we conducted a genetic association analysis of case-control samples (325 MDD patients, 154 BP patients and 807 controls) in the Japanese population. In addition, we performed an association analysis between NOS1 and the efficacy of fluvoxamine treatment in 117 MDD patients. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D (Structured Interview Guide for the Hamilton Rating Scale for Depression) score within 8 weeks, and clinical remission as an SIGH-D score of less than 7 at 8 weeks. Results: We did not detect a significant association between NOS1 and MDD, BP or the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis. Conclusions: We did not detect an association between only one marker (rs41279104) in NOS1 and Japanese mood disorder patients and fluvoxamine response, but sample sizes were probably too small to allow a meaningful test. Moreover, because we did not perform an association analysis based on linkage disequilibrium and a mutation scan of NOS1, a replication of the study using a larger sample and based on linkage disequilibrium may be required for conclusive results.

show abstract

“…However, others have reported a wide variability in the range of plasma concentrations among responders and found no correlation with dosage. 16,17) Thus, available data do not indicate benefits from routine monitoring of plasma fluvoxamine concentration.…”

mentioning

confidence: 99%

Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients

Katoh

Uchida

Kawai

et al. 2010

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

Cited by 73 publications

References 24 publications

Association between -1438G/A Promoter Polymorphism in the 5-HT<sub>2A</sub> Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder

Association between -1438G/A Promoter Polymorphism in the 5-HT<sub>2A</sub> Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder

Genetic Association Analysis of Functional Polymorphisms in Neuronal Nitric Oxide Synthase 1 Gene <i>(NOS1)</i> and Mood Disorders and Fluvoxamine Response in Major Depressive Disorder in the Japanese Population

Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients

Contact Info

Product

Resources

About